Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.46 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519109 | 0.86 | TLK2 (0.57) | PDPK1TLK2KMT2AJAK3CDK1 | |
| SCHEMBL5364317 | 0.83 | AKT2 (0.48) | PDPK1TLK2NEK2 | |
| SCHEMBL5368073 | 0.83 | PDPK1 (0.61) | PDPK1TLK2JAK3NEK2CDK1 | |
| SCHEMBL5365829 | 0.81 | PDPK1 (0.48) | PDPK1TLK2EGFRNEK2CDK1 | |
| SCHEMBL5358704 | 0.80 | AKT2 (0.60) | PDPK1 | |
| SCHEMBL6001532 | 0.79 | LRRK2 (0.58) | EGFR | |
| SCHEMBL6001533 | 0.79 | LRRK2 (0.58) | EGFR | |
| SCHEMBL5359077 | 0.79 | EGFR (0.47) | PDPK1EGFRALDH1A1MAPTTHRB | |
| SCHEMBL5367195 | 0.79 | PDPK1 (0.57) | PDPK1EGFRALDH1A1MAPTTHRB | |
| SCHEMBL5366834 | 0.78 | GSK3B (0.52) | TLK2EGFRMAPTJAK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PDPK1 31/4885TLK2 48/4885EGFR 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.